EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?

Birol Ocak iD, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Goktas Aydın, Ali Gökyer, Ahmet Kücükarda und 18 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31090384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Birol Ocak und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa 16350, Turkey. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell, Kidney Neoplasms, Nephrectomy. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the failure of at least one anti-vascular endothelial growth factor (VEGF) agent in patients with metastatic clear-cell renal-cell carcinoma (ccRCC).

Methods

We included 106 de novo metastatic ccRCC patients who received nivolumab after progression on at least one anti-VEGF agent. Multivariate Cox regression analysis was performed to investigate the factors affecting survival in patients receiving nivolumab.

Results

Of the 106 de novo metastatic ccRCC patients, 83 (78.3%) underwent CN. There were no statistical differences between the two groups in terms of age, gender, Eastern Cooperative Oncology Group (ECOG) score, tumor size, International Metastatic RCC Database Consortium (IMDC) risk group, number of previous treatment lines, first-line anti-VEGF therapy, or metastasis sites (p = 0.137, p = 0.608, p = 0.100, p = 0.376, p = 0.185, p = 0.776, p = 0.350, and p = 0.608, respectively). The patients who received nivolumab with CN had a longer time to treatment discontinuation (TTD) [14.5 months, 95% confidence interval (CI): 8.6–20.3] than did those without CN 6.7 months (95% CI: 3.9–9.5) (p = 0.001). The median overall survival (OS) was 22.7 months (95% CI: 16.1–29.4). The patients with CN had a median OS of 22.9 months (95% CI: 16.3–29.4), while those without CN had a median OS of 8.1 months (95% CI: 5.6–10.5) (p = 0.104). In the multivariate analysis, CN [hazard ratio (HR): 0.521; 95% CI: 0.297–0.916; p = 0.024] and the IMDC risk score (p = 0.011) were statistically significant factors affecting TTD; however, the IMDC risk score (p = 0.006) was the only significant factor for overall survival.

Conclusions

Our study showed that the TTD of nivolumab was longer in metastatic ccRCC patients who underwent cytoreductive nephrectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabCarcinoma, Renal CellKidney NeoplasmsNephrectomyCytoreduction Surgical ProceduresHumansMaleFemaleMiddle AgedAgedTreatment OutcomeAdultRetrospective StudiesAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

clear-cell renal-cell carcinomacytoreductive nephrectomynivolumabsurvival

Substanzen

NivolumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Medical Oncology, Bursa Yuksek Ihtisas Training and Research Hospital, University of Health Sciences, Bursa 16350, Turkey.
  • Department of Medical Oncology, School of Medicine, Bursa Uludag University, Bursa 16059, Turkey.
  • Department of Medical Oncology, Gulhane School of Medicine, University of Health Sciences, Ankara 06018, Turkey.
  • Department of Medical Oncology, School of Medicine, Necmettin Erbakan University, Konya 42090, Turkey.
  • Department of Medical Oncology, VM Medical Park Samsun Hospital, Samsun 55200, Turkey.
  • Department of Medical Oncology, Van Training and Research Hospital, University of Health Sciences, Van 65300, Turkey.

ORCID-Profile: Birol Ocak, Ayse Irem Yasin, Bahar Dakiki, Nazım Serdar Turhal

Zitieren

APA

Ocak, B., Sahin, A. B., Ertürk, I., Korkmaz, M., Erdem, D., Cakıroglu, U., Karaca, M., Dirican, A., Olmez, O. F., Goktas Aydın, S., Gökyer, A., Kücükarda, A., Gülmez, A., Yumuk, P. F., Demircan, N. C., Oyman, A., Sakalar, T., Karatas, F., Demir, H., …, & Evrensel, T. (2024). Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?. Current Oncology. https://doi.org/10.3390/curroncol31090384

Vancouver

Ocak B, Sahin AB, Ertürk I, Korkmaz M, Erdem D, Cakıroglu U, et al. Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?. Current Oncology. 2024. doi:10.3390/curroncol31090384

BibTeX
@article{Ocak2024,
  author = {Ocak, Birol and Sahin, Ahmet Bilgehan and Ertürk, Ismail and Korkmaz, Mustafa and Erdem, Dilek and Cakıroglu, Umut and Karaca, Mustafa and Dirican, Ahmet and Olmez, Omer Fatih and Goktas Aydın, Sabin and Gökyer, Ali and Kücükarda, Ahmet and Gülmez, Ahmet and Yumuk, Perran Fulden and Demircan, Nazim Can and Oyman, Abdilkerim and Sakalar, Teoman and Karatas, Fatih and Demir, Hacer and Yasin, Ayse Irem and Deligonul, Adem and Dakiki, Bahar and Goktug, Mehmet Refik and Avcı, Okan and Tacar, Seher Yildiz and Turhal, Nazım Serdar and Deniz, Gülhan Ipek and Kacan, Turgut and Cubukcu, Erdem and Evrensel, Türkkan},
  title = {Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma?},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31090384}
}
Kostenlos starten →